Opioid-Induced Constipation Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Opioid-Induced Constipation market size was valued at USD 2604.3 million in 2022 and is forecast to a readjusted size of USD 3520.9 million by 2029 with a CAGR of 4.4% during review period.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%. North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent. In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

This report is a detailed and comprehensive analysis for global Opioid-Induced Constipation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Opioid-Induced Constipation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Opioid-Induced Constipation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Opioid-Induced Constipation market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Takeda Pharmaceuticals
   Bayer
   Sanofi
   Mallinckrodt
   Salix (Bausch Health)
   AstraZeneca
   Progenics Pharmaceuticals
   Purdue Pharm
   Nektar Therapeutics
   Daiichi Sankyo
   Prestige
   GSK
   Shionogi

   Methylnaltrexone Bromide
   Lubiprostone
   Naloxegol
   Others

   Hospital
   Pharmacy
   Other

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Opioid-Induced Constipation Market 2025?

The strength lies in the growing prevalence of opioid use globally, which increases the demand for treatments for opioid-induced constipation (OIC). The market benefits from advancements in pharmaceutical treatments and an increased focus on patient care in managing OIC, making it a vital segment within the larger healthcare market.

What are the weaknesses of the Opioid-Induced Constipation Market 2025?

One weakness is the underdiagnosis of OIC in patients, as it is often overlooked in favor of addressing opioid addiction. Additionally, the high cost of new treatments may limit access for many patients, and the market is still heavily reliant on a few key therapeutic options, restricting growth potential.

What opportunities exist in the Opioid-Induced Constipation Market 2025?

There is a significant opportunity in developing more effective, affordable, and patient-friendly treatments for OIC. The growing awareness of OIC among healthcare professionals and patients opens avenues for novel drug formulations and delivery methods, along with the expansion into emerging markets where opioid use is rising.

What are the threats to the Opioid-Induced Constipation Market 2025?

The market faces threats from regulatory challenges, as there is increasing scrutiny on opioid usage and its related side effects, including constipation. Moreover, the potential for competition from non-pharmaceutical interventions, such as lifestyle and dietary changes, may pose a risk to pharmaceutical-based treatment market share.

What political factors influence the Opioid-Induced Constipation Market 2025?

Political factors such as government regulations surrounding opioid prescriptions and policies related to pain management impact the market. Increasing government efforts to combat opioid addiction and misuse may lead to stricter controls, which could either limit the use of opioids or drive demand for effective treatments for opioid-induced constipation.

How do economic factors affect the Opioid-Induced Constipation Market 2025?

Economic factors like healthcare spending, insurance coverage, and the affordability of new treatments play a significant role. In countries with strong healthcare systems, the market can thrive due to greater access to treatments, whereas in regions with economic challenges, cost constraints could limit the uptake of advanced therapies for OIC.

What social factors impact the Opioid-Induced Constipation Market 2025?

Social factors, including increasing awareness of opioid-related side effects and growing patient advocacy for better treatment options, are positively influencing the market. As the public becomes more aware of opioid-induced constipation, there is a rising demand for effective therapies and improved patient education.

What technological factors are relevant to the Opioid-Induced Constipation Market 2025?

Technological advancements in drug formulation, delivery methods, and diagnostic tools for OIC are crucial. The development of more targeted therapies, such as opioid receptor antagonists, and the use of digital health solutions to monitor and manage symptoms, are shaping the future of this market.

What environmental factors are important for the Opioid-Induced Constipation Market 2025?

Environmental factors such as the growing focus on sustainability and eco-friendly practices in pharmaceutical manufacturing can impact the market. Additionally, there may be regulatory pressures for environmentally safe disposal of opioid medications and related waste, influencing production processes.

What legal factors affect the Opioid-Induced Constipation Market 2025?

Legal factors include the regulatory approval process for new treatments, intellectual property protections, and liability concerns related to opioid use. Stricter regulations on opioid prescriptions could drive up demand for OIC treatments, while legal challenges around opioid misuse and lawsuits may create barriers for pharmaceutical companies.

Who are the suppliers in the Opioid-Induced Constipation Market 2025?

Suppliers in the Opioid-Induced Constipation Market include pharmaceutical companies, biotechnology firms, and raw material suppliers involved in the production of medications designed to treat OIC. These suppliers also include research institutions that innovate new treatments and delivery methods.

What inputs are required for the Opioid-Induced Constipation Market 2025?

The inputs required include active pharmaceutical ingredients (APIs), clinical research data, regulatory approvals, and manufacturing technologies. These inputs are essential for the development of new drugs and treatments for OIC, as well as for ensuring safety and efficacy.

What processes are involved in the Opioid-Induced Constipation Market 2025?

The processes involve research and development (R&D) of new medications, clinical trials to test their safety and effectiveness, regulatory approval, manufacturing of pharmaceutical products, and distribution through healthcare providers and pharmacies. Education and awareness campaigns also play a role in promoting these treatments.

Who are the customers in the Opioid-Induced Constipation Market 2025?

The customers include healthcare providers, hospitals, pharmacies, and most importantly, patients who suffer from opioid-induced constipation. Patients, who are often opioid users for chronic pain, seek effective treatments for OIC, making them the central focus of the market.

What are the outputs of the Opioid-Induced Constipation Market 2025?

The outputs include approved pharmaceutical treatments, improved patient outcomes, reduced symptoms of OIC, and increased awareness of OIC as a medical condition. These outputs contribute to a more manageable quality of life for patients and greater market demand for specialized treatments.

How intense is the threat of new entrants in the Opioid-Induced Constipation Market 2025?

The threat of new entrants is moderate. While the market offers growth potential due to increasing opioid use, the high barriers to entry, including regulatory hurdles, significant R&D investments, and the need for proven efficacy in drug development, limit the ability of new companies to easily enter the market.

How strong is the bargaining power of suppliers in the Opioid-Induced Constipation Market 2025?

The bargaining power of suppliers is moderate. Key suppliers, such as raw material providers and biotech firms, can influence prices and supply chains, but large pharmaceutical companies have the leverage to negotiate favorable terms due to their buying power and established relationships in the industry.

How intense is the threat of substitute products in the Opioid-Induced Constipation Market 2025?

The threat of substitutes is moderate. Non-pharmaceutical approaches like lifestyle changes, dietary modifications, and over-the-counter remedies may reduce reliance on prescription treatments for OIC. However, for patients suffering from more severe symptoms, prescription medications remain the preferred option.

How strong is the bargaining power of buyers in the Opioid-Induced Constipation Market 2025?

The bargaining power of buyers is low to moderate. While patients and healthcare providers have a degree of influence over treatment choices, the availability of specialized OIC drugs and the relatively limited number of effective therapies mean that pharmaceutical companies hold a significant amount of power in setting prices.

How competitive is the rivalry among existing competitors in the Opioid-Induced Constipation Market 2025?

The rivalry among existing competitors is moderate to high. The market is still evolving with a few established players offering solutions for OIC, and new competitors continue to innovate. Companies are competing based on product efficacy, safety profiles, and pricing, driving constant pressure to improve offerings.

What are the key suppliers in the Opioid-Induced Constipation Market 2025?

Key suppliers include pharmaceutical companies that develop medications for opioid-induced constipation (OIC), raw material suppliers providing active pharmaceutical ingredients (APIs), and contract research organizations (CROs) that conduct clinical trials for drug development.

What raw materials and resources are critical in the Opioid-Induced Constipation Market 2025?

Critical resources include active pharmaceutical ingredients (APIs) such as opioid antagonists and other compounds specifically targeting OIC, as well as excipients for drug formulation. Additionally, advanced manufacturing technologies, clinical research data, and regulatory approvals are essential components.

What are the major challenges in the upstream supply chain for the Opioid-Induced Constipation Market 2025?

Challenges include stringent regulatory requirements for drug approval, rising costs of raw materials, and the complexity of developing effective treatments for OIC. Additionally, ensuring consistent quality and compliance across the supply chain is an ongoing concern for manufacturers.

What technological advancements impact the upstream supply chain in the Opioid-Induced Constipation Market 2025?

Technological advancements such as improvements in drug formulation, advanced manufacturing techniques, and more efficient clinical trial processes can enhance the upstream supply chain. Innovations in personalized medicine and drug delivery systems also play a role in improving treatment efficacy and patient compliance.

What regulatory factors affect the upstream supply chain in the Opioid-Induced Constipation Market 2025?

Regulatory factors include the approval process for new medications, which involves extensive clinical trials and compliance with local and international health authorities. Regulations surrounding the use of opioids, including prescription monitoring and safety protocols, also influence the upstream supply chain, especially in terms of market access and production constraints.

What are the key players in the midstream of the Opioid-Induced Constipation Market 2025?

Key players in the midstream include pharmaceutical companies that manufacture and distribute medications for opioid-induced constipation (OIC), healthcare providers like hospitals and clinics that administer treatments, and distributors who facilitate the movement of drugs from manufacturers to end-users.

What are the critical processes involved in the midstream of the Opioid-Induced Constipation Market 2025?

The critical processes include drug manufacturing, packaging, distribution, and ensuring compliance with regulatory standards. The supply chain also involves inventory management and collaboration with healthcare providers to ensure timely delivery of effective OIC treatments to patients.

What challenges do companies face in the midstream of the Opioid-Induced Constipation Market 2025?

Companies face challenges such as managing drug shortages, maintaining the cold chain for temperature-sensitive medications, and ensuring timely and cost-effective distribution. Additionally, healthcare providers may face difficulties in identifying and diagnosing OIC, affecting demand for treatment in the midstream.

How does the healthcare ecosystem influence the midstream of the Opioid-Induced Constipation Market 2025?

The healthcare ecosystem impacts the midstream by influencing demand for OIC treatments. The availability of insurance coverage, reimbursement policies, and the healthcare infrastructure in different regions play a significant role in shaping distribution and access to medications for patients.

What role does innovation play in the midstream of the Opioid-Induced Constipation Market 2025?

Innovation plays a key role in improving the efficiency of distribution and the development of new drug formulations. The advent of patient-centric delivery systems, like oral formulations and injectable options, as well as improved distribution technologies, can help streamline the midstream and make treatments more accessible.

Who are the key stakeholders in the downstream of the Opioid-Induced Constipation Market 2025?

Key stakeholders include healthcare providers such as doctors, specialists, and nurses who diagnose and treat opioid-induced constipation (OIC), patients suffering from OIC, pharmacies that dispense medications, and insurance companies that provide coverage for OIC treatments.

What are the critical processes in the downstream of the Opioid-Induced Constipation Market 2025?

Critical processes include the diagnosis of OIC by healthcare providers, prescription of appropriate medications, patient education on managing OIC, and the dispensing of medications at pharmacies. Additionally, insurance claims and reimbursement processes play a vital role in ensuring patient access to treatments.

What challenges are faced in the downstream of the Opioid-Induced Constipation Market 2025?

Challenges include underdiagnosis and mismanagement of OIC due to insufficient awareness among healthcare providers, delays in medication access due to insurance and reimbursement issues, and limited patient adherence to prescribed treatments due to side effects or convenience concerns.

How does patient awareness affect the downstream of the Opioid-Induced Constipation Market 2025?

Patient awareness directly impacts the downstream by influencing demand for OIC treatments. As awareness of OIC increases, patients are more likely to seek treatment, driving higher demand for medications. Additionally, educated patients are more likely to adhere to prescribed therapies and improve treatment outcomes.

What role do healthcare providers play in the downstream of the Opioid-Induced Constipation Market 2025?

Healthcare providers play a crucial role by diagnosing OIC, recommending appropriate treatments, and monitoring patient progress. Their awareness of the condition and ability to manage opioid therapy effectively are key factors that determine the success of OIC treatment strategies in the downstream.

Chapter 1, to describe Opioid-Induced Constipation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Opioid-Induced Constipation, with price, sales, revenue and global market share of Opioid-Induced Constipation from 2018 to 2023.
Chapter 3, the Opioid-Induced Constipation competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Opioid-Induced Constipation breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Opioid-Induced Constipation.
Chapter 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Opioid-Induced Constipation
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global Opioid-Induced Constipation Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Methylnaltrexone Bromide
       1.3.3 Lubiprostone
       1.3.4 Naloxegol
       1.3.5 Others
   1.4 Market Analysis by Application
       1.4.1 Overview: Global Opioid-Induced Constipation Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Hospital
       1.4.3 Pharmacy
       1.4.4 Other
   1.5 Global Opioid-Induced Constipation Market Size & Forecast
       1.5.1 Global Opioid-Induced Constipation Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Opioid-Induced Constipation Sales Quantity (2018-2029)
       1.5.3 Global Opioid-Induced Constipation Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 Takeda Pharmaceuticals
       2.1.1 Takeda Pharmaceuticals Details
       2.1.2 Takeda Pharmaceuticals Major Business
       2.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
       2.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Takeda Pharmaceuticals Recent Developments/Updates
   2.2 Bayer
       2.2.1 Bayer Details
       2.2.2 Bayer Major Business
       2.2.3 Bayer Opioid-Induced Constipation Product and Services
       2.2.4 Bayer Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Bayer Recent Developments/Updates
   2.3 Sanofi
       2.3.1 Sanofi Details
       2.3.2 Sanofi Major Business
       2.3.3 Sanofi Opioid-Induced Constipation Product and Services
       2.3.4 Sanofi Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Sanofi Recent Developments/Updates
   2.4 Mallinckrodt
       2.4.1 Mallinckrodt Details
       2.4.2 Mallinckrodt Major Business
       2.4.3 Mallinckrodt Opioid-Induced Constipation Product and Services
       2.4.4 Mallinckrodt Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Mallinckrodt Recent Developments/Updates
   2.5 Salix (Bausch Health)
       2.5.1 Salix (Bausch Health) Details
       2.5.2 Salix (Bausch Health) Major Business
       2.5.3 Salix (Bausch Health) Opioid-Induced Constipation Product and Services
       2.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Salix (Bausch Health) Recent Developments/Updates
   2.6 AstraZeneca
       2.6.1 AstraZeneca Details
       2.6.2 AstraZeneca Major Business
       2.6.3 AstraZeneca Opioid-Induced Constipation Product and Services
       2.6.4 AstraZeneca Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 AstraZeneca Recent Developments/Updates
   2.7 Progenics Pharmaceuticals
       2.7.1 Progenics Pharmaceuticals Details
       2.7.2 Progenics Pharmaceuticals Major Business
       2.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
       2.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Progenics Pharmaceuticals Recent Developments/Updates
   2.8 Purdue Pharm
       2.8.1 Purdue Pharm Details
       2.8.2 Purdue Pharm Major Business
       2.8.3 Purdue Pharm Opioid-Induced Constipation Product and Services
       2.8.4 Purdue Pharm Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Purdue Pharm Recent Developments/Updates
   2.9 Nektar Therapeutics
       2.9.1 Nektar Therapeutics Details
       2.9.2 Nektar Therapeutics Major Business
       2.9.3 Nektar Therapeutics Opioid-Induced Constipation Product and Services
       2.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Nektar Therapeutics Recent Developments/Updates
   2.10 Daiichi Sankyo
       2.10.1 Daiichi Sankyo Details
       2.10.2 Daiichi Sankyo Major Business
       2.10.3 Daiichi Sankyo Opioid-Induced Constipation Product and Services
       2.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Daiichi Sankyo Recent Developments/Updates
   2.11 Prestige
       2.11.1 Prestige Details
       2.11.2 Prestige Major Business
       2.11.3 Prestige Opioid-Induced Constipation Product and Services
       2.11.4 Prestige Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Prestige Recent Developments/Updates
   2.12 GSK
       2.12.1 GSK Details
       2.12.2 GSK Major Business
       2.12.3 GSK Opioid-Induced Constipation Product and Services
       2.12.4 GSK Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 GSK Recent Developments/Updates
   2.13 Shionogi
       2.13.1 Shionogi Details
       2.13.2 Shionogi Major Business
       2.13.3 Shionogi Opioid-Induced Constipation Product and Services
       2.13.4 Shionogi Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 Shionogi Recent Developments/Updates

3 Competitive Environment: Opioid-Induced Constipation by Manufacturer

   3.1 Global Opioid-Induced Constipation Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Opioid-Induced Constipation Revenue by Manufacturer (2018-2023)
   3.3 Global Opioid-Induced Constipation Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Opioid-Induced Constipation by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Opioid-Induced Constipation Manufacturer Market Share in 2022
       3.4.2 Top 6 Opioid-Induced Constipation Manufacturer Market Share in 2022
   3.5 Opioid-Induced Constipation Market: Overall Company Footprint Analysis
       3.5.1 Opioid-Induced Constipation Market: Region Footprint
       3.5.2 Opioid-Induced Constipation Market: Company Product Type Footprint
       3.5.3 Opioid-Induced Constipation Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Opioid-Induced Constipation Market Size by Region
       4.1.1 Global Opioid-Induced Constipation Sales Quantity by Region (2018-2029)
       4.1.2 Global Opioid-Induced Constipation Consumption Value by Region (2018-2029)
       4.1.3 Global Opioid-Induced Constipation Average Price by Region (2018-2029)
   4.2 North America Opioid-Induced Constipation Consumption Value (2018-2029)
   4.3 Europe Opioid-Induced Constipation Consumption Value (2018-2029)
   4.4 Asia-Pacific Opioid-Induced Constipation Consumption Value (2018-2029)
   4.5 South America Opioid-Induced Constipation Consumption Value (2018-2029)
   4.6 Middle East and Africa Opioid-Induced Constipation Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   5.2 Global Opioid-Induced Constipation Consumption Value by Type (2018-2029)
   5.3 Global Opioid-Induced Constipation Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   6.2 Global Opioid-Induced Constipation Consumption Value by Application (2018-2029)
   6.3 Global Opioid-Induced Constipation Average Price by Application (2018-2029)

7 North America

   7.1 North America Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   7.2 North America Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   7.3 North America Opioid-Induced Constipation Market Size by Country
       7.3.1 North America Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
       7.3.2 North America Opioid-Induced Constipation Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   8.2 Europe Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   8.3 Europe Opioid-Induced Constipation Market Size by Country
       8.3.1 Europe Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
       8.3.2 Europe Opioid-Induced Constipation Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific Opioid-Induced Constipation Market Size by Region
       9.3.1 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   10.2 South America Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   10.3 South America Opioid-Induced Constipation Market Size by Country
       10.3.1 South America Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
       10.3.2 South America Opioid-Induced Constipation Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa Opioid-Induced Constipation Market Size by Country
       11.3.1 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Opioid-Induced Constipation Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Opioid-Induced Constipation Market Drivers
   12.2 Opioid-Induced Constipation Market Restraints
   12.3 Opioid-Induced Constipation Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Opioid-Induced Constipation and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Opioid-Induced Constipation
   13.3 Opioid-Induced Constipation Production Process
   13.4 Opioid-Induced Constipation Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Opioid-Induced Constipation Typical Distributors
   14.3 Opioid-Induced Constipation Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Opioid-Induced Constipation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Opioid-Induced Constipation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 4. Takeda Pharmaceuticals Major Business
   Table 5. Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
   Table 6. Takeda Pharmaceuticals Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. Takeda Pharmaceuticals Recent Developments/Updates
   Table 8. Bayer Basic Information, Manufacturing Base and Competitors
   Table 9. Bayer Major Business
   Table 10. Bayer Opioid-Induced Constipation Product and Services
   Table 11. Bayer Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. Bayer Recent Developments/Updates
   Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
   Table 14. Sanofi Major Business
   Table 15. Sanofi Opioid-Induced Constipation Product and Services
   Table 16. Sanofi Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. Sanofi Recent Developments/Updates
   Table 18. Mallinckrodt Basic Information, Manufacturing Base and Competitors
   Table 19. Mallinckrodt Major Business
   Table 20. Mallinckrodt Opioid-Induced Constipation Product and Services
   Table 21. Mallinckrodt Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. Mallinckrodt Recent Developments/Updates
   Table 23. Salix (Bausch Health) Basic Information, Manufacturing Base and Competitors
   Table 24. Salix (Bausch Health) Major Business
   Table 25. Salix (Bausch Health) Opioid-Induced Constipation Product and Services
   Table 26. Salix (Bausch Health) Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Salix (Bausch Health) Recent Developments/Updates
   Table 28. AstraZeneca Basic Information, Manufacturing Base and Competitors
   Table 29. AstraZeneca Major Business
   Table 30. AstraZeneca Opioid-Induced Constipation Product and Services
   Table 31. AstraZeneca Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 32. AstraZeneca Recent Developments/Updates
   Table 33. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 34. Progenics Pharmaceuticals Major Business
   Table 35. Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
   Table 36. Progenics Pharmaceuticals Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 37. Progenics Pharmaceuticals Recent Developments/Updates
   Table 38. Purdue Pharm Basic Information, Manufacturing Base and Competitors
   Table 39. Purdue Pharm Major Business
   Table 40. Purdue Pharm Opioid-Induced Constipation Product and Services
   Table 41. Purdue Pharm Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 42. Purdue Pharm Recent Developments/Updates
   Table 43. Nektar Therapeutics Basic Information, Manufacturing Base and Competitors
   Table 44. Nektar Therapeutics Major Business
   Table 45. Nektar Therapeutics Opioid-Induced Constipation Product and Services
   Table 46. Nektar Therapeutics Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 47. Nektar Therapeutics Recent Developments/Updates
   Table 48. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
   Table 49. Daiichi Sankyo Major Business
   Table 50. Daiichi Sankyo Opioid-Induced Constipation Product and Services
   Table 51. Daiichi Sankyo Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 52. Daiichi Sankyo Recent Developments/Updates
   Table 53. Prestige Basic Information, Manufacturing Base and Competitors
   Table 54. Prestige Major Business
   Table 55. Prestige Opioid-Induced Constipation Product and Services
   Table 56. Prestige Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 57. Prestige Recent Developments/Updates
   Table 58. GSK Basic Information, Manufacturing Base and Competitors
   Table 59. GSK Major Business
   Table 60. GSK Opioid-Induced Constipation Product and Services
   Table 61. GSK Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 62. GSK Recent Developments/Updates
   Table 63. Shionogi Basic Information, Manufacturing Base and Competitors
   Table 64. Shionogi Major Business
   Table 65. Shionogi Opioid-Induced Constipation Product and Services
   Table 66. Shionogi Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 67. Shionogi Recent Developments/Updates
   Table 68. Global Opioid-Induced Constipation Sales Quantity by Manufacturer (2018-2023) & (K Units)
   Table 69. Global Opioid-Induced Constipation Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 70. Global Opioid-Induced Constipation Average Price by Manufacturer (2018-2023) & (USD/Unit)
   Table 71. Market Position of Manufacturers in Opioid-Induced Constipation, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 72. Head Office and Opioid-Induced Constipation Production Site of Key Manufacturer
   Table 73. Opioid-Induced Constipation Market: Company Product Type Footprint
   Table 74. Opioid-Induced Constipation Market: Company Product Application Footprint
   Table 75. Opioid-Induced Constipation New Market Entrants and Barriers to Market Entry
   Table 76. Opioid-Induced Constipation Mergers, Acquisition, Agreements, and Collaborations
   Table 77. Global Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
   Table 78. Global Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
   Table 79. Global Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
   Table 80. Global Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
   Table 81. Global Opioid-Induced Constipation Average Price by Region (2018-2023) & (USD/Unit)
   Table 82. Global Opioid-Induced Constipation Average Price by Region (2024-2029) & (USD/Unit)
   Table 83. Global Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 84. Global Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 85. Global Opioid-Induced Constipation Consumption Value by Type (2018-2023) & (USD Million)
   Table 86. Global Opioid-Induced Constipation Consumption Value by Type (2024-2029) & (USD Million)
   Table 87. Global Opioid-Induced Constipation Average Price by Type (2018-2023) & (USD/Unit)
   Table 88. Global Opioid-Induced Constipation Average Price by Type (2024-2029) & (USD/Unit)
   Table 89. Global Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 90. Global Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 91. Global Opioid-Induced Constipation Consumption Value by Application (2018-2023) & (USD Million)
   Table 92. Global Opioid-Induced Constipation Consumption Value by Application (2024-2029) & (USD Million)
   Table 93. Global Opioid-Induced Constipation Average Price by Application (2018-2023) & (USD/Unit)
   Table 94. Global Opioid-Induced Constipation Average Price by Application (2024-2029) & (USD/Unit)
   Table 95. North America Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 96. North America Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 97. North America Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 98. North America Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 99. North America Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
   Table 100. North America Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
   Table 101. North America Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
   Table 102. North America Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
   Table 103. Europe Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 104. Europe Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 105. Europe Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 106. Europe Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 107. Europe Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
   Table 108. Europe Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
   Table 109. Europe Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
   Table 110. Europe Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
   Table 111. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 112. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 113. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 114. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 115. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
   Table 116. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
   Table 117. Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
   Table 118. Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
   Table 119. South America Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 120. South America Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 121. South America Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 122. South America Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 123. South America Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
   Table 124. South America Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
   Table 125. South America Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
   Table 126. South America Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
   Table 127. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
   Table 128. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
   Table 129. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
   Table 130. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
   Table 131. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
   Table 132. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
   Table 133. Middle East & Africa Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
   Table 134. Middle East & Africa Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
   Table 135. Opioid-Induced Constipation Raw Material
   Table 136. Key Manufacturers of Opioid-Induced Constipation Raw Materials
   Table 137. Opioid-Induced Constipation Typical Distributors
   Table 138. Opioid-Induced Constipation Typical Customers

List of Figures

   Figure 1. Opioid-Induced Constipation Picture
   Figure 2. Global Opioid-Induced Constipation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Opioid-Induced Constipation Consumption Value Market Share by Type in 2022
   Figure 4. Methylnaltrexone Bromide Examples
   Figure 5. Lubiprostone Examples
   Figure 6. Naloxegol Examples
   Figure 7. Others Examples
   Figure 8. Global Opioid-Induced Constipation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 9. Global Opioid-Induced Constipation Consumption Value Market Share by Application in 2022
   Figure 10. Hospital Examples
   Figure 11. Pharmacy Examples
   Figure 12. Other Examples
   Figure 13. Global Opioid-Induced Constipation Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 14. Global Opioid-Induced Constipation Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 15. Global Opioid-Induced Constipation Sales Quantity (2018-2029) & (K Units)
   Figure 16. Global Opioid-Induced Constipation Average Price (2018-2029) & (USD/Unit)
   Figure 17. Global Opioid-Induced Constipation Sales Quantity Market Share by Manufacturer in 2022
   Figure 18. Global Opioid-Induced Constipation Consumption Value Market Share by Manufacturer in 2022
   Figure 19. Producer Shipments of Opioid-Induced Constipation by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 20. Top 3 Opioid-Induced Constipation Manufacturer (Consumption Value) Market Share in 2022
   Figure 21. Top 6 Opioid-Induced Constipation Manufacturer (Consumption Value) Market Share in 2022
   Figure 22. Global Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
   Figure 23. Global Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
   Figure 24. North America Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
   Figure 25. Europe Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
   Figure 26. Asia-Pacific Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
   Figure 27. South America Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
   Figure 28. Middle East & Africa Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
   Figure 29. Global Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 30. Global Opioid-Induced Constipation Consumption Value Market Share by Type (2018-2029)
   Figure 31. Global Opioid-Induced Constipation Average Price by Type (2018-2029) & (USD/Unit)
   Figure 32. Global Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 33. Global Opioid-Induced Constipation Consumption Value Market Share by Application (2018-2029)
   Figure 34. Global Opioid-Induced Constipation Average Price by Application (2018-2029) & (USD/Unit)
   Figure 35. North America Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 36. North America Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 37. North America Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
   Figure 38. North America Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
   Figure 39. United States Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Canada Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 41. Mexico Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 42. Europe Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 43. Europe Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 44. Europe Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
   Figure 45. Europe Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
   Figure 46. Germany Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. France Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. United Kingdom Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Russia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 50. Italy Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 51. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 52. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 53. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
   Figure 54. Asia-Pacific Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
   Figure 55. China Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. Japan Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. Korea Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. India Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. Southeast Asia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 60. Australia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 61. South America Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 62. South America Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 63. South America Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
   Figure 64. South America Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
   Figure 65. Brazil Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 66. Argentina Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 67. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
   Figure 68. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
   Figure 69. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
   Figure 70. Middle East & Africa Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
   Figure 71. Turkey Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. Egypt Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. Saudi Arabia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 74. South Africa Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 75. Opioid-Induced Constipation Market Drivers
   Figure 76. Opioid-Induced Constipation Market Restraints
   Figure 77. Opioid-Induced Constipation Market Trends
   Figure 78. Porters Five Forces Analysis
   Figure 79. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2022
   Figure 80. Manufacturing Process Analysis of Opioid-Induced Constipation
   Figure 81. Opioid-Induced Constipation Industrial Chain
   Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 83. Direct Channel Pros & Cons
   Figure 84. Indirect Channel Pros & Cons
   Figure 85. Methodology
   Figure 86. Research Process and Data Source